Multiple Sklerose (MS) und Neuroborreliose
Multiple sclerosis and neuroborreliosis

Levin, MC, Douglas, JN, Meyers, L. (2014) **Neurodegeneration in multiple sclerosis involves multiple pathogenic mechanisms.** Degener Neurol Neuromuscul Dis 4, 49–63. Google Scholar
https://www.google.de/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0ahUKEwiAl6GWwvLXAhVDuBQKHUyrAqYQFggxMAA&url=https%3A%2F%2Fwww.dovepress.com%2Fneurodegeneration-in-multiple-sclerosis-involves-multiple-pathogenic-m-peer-reviewed-article-DNND&usg=AOvVaw1UI3_SrBNnfurswr6xhLgt

Virusarten, viruses

Perron H, Perin JP, Rieger F, Alliel PM (2000), Firouzi R, Rolland A, Michel M, (2003), Christensen T. (2005), Levin LI et. al. (2005), Perron H, Bernard C, Bertrand JB et al. (2009), Cossu D, Masala S, Cocco E et al. (2012), Djelilovic-Vranic J, Alajbegovic A. (2012), Tselis A (2012), Olival GS, Lima BM, Sumita LM, Serafim V, Fink MC, Nali LH et al. (2013), Mameli G, Madeddu G, Mei A et al. (2013), Angelini DF, Serafini B, Piras E et al. (2013), Garcia-Montojo M, Dominguez-Mozo M, Arias-Leal A et al. (2013), Mancuso R, Saresella M, Hernis A et al. (2013), García-Montojo M, de la Hera B, Varadé J, et al. (2014), Sutherland S (2014), Mameli G, Cossu D, Cocco E et al. (2014), Lossius A, Johansen JN, Vartdal F et al. (2014), Mechelli R, Manzari C, Policano C (2015), Campbell A (2017), Hassani A (2018), Pender MP (2018)

- **Virus triggers http://www.erlebnishaft.de/virustriggers.pdf**
- **Anderson SM, Klinken SP, Hankins WD. (1985) A murine recombinant retrovirus (MSRV) containing the src oncogene transforms erythroid precursor cells in vitro. Mol Cell Biol. 5(12), 3369-3375. http://www.ncbi.nlm.nih.gov/pubmed/3939314**
- **MSRV http://ac.els-cdn.com/S0042682299997921/1-s2.0-S0042682299997921-main.pdf?_tid=1a58bdc4-4f9a-11e3-99d6-00000aacb361&acdnat=1384701083_7c037e9ebe7e39bd42b0ab26be8610a1**
- **MSRV http://hal.inria.fr/docs/00/06/66/67/PDF/Rolland_et_al_Journal_of_Immunology_In_Press.pdf**

Bakterien, bacteria

Spirochaeten im extra Kästchen unten,
spirocheta see below, extra box.
Rostasy K, Reiber H, Pohl D et al. (2003), Cossu D, Masala S, Cocco E et al. (2012), Chen J (2016), Jangi S (2016), Barazin SE (2017, 2018), Tankou SK (2018), Kriesel JD (2019)

- **Mycobacteria http://www.kabilahsystems.de/atypical_mycobacteria.pdf**
  http://www.ncbi.nlm.nih.gov/pubmed?LinkName=pubmed_pubmed&from_uid=23439580
- **Chlamydien, Chlamydophila**
  http://www.kabilahsystems.de/chlamydia_pneumoniae.pdf

Protozoen, protozoa

Kissler H. (2001)

- **Apicomplexa http://www.kabilahsystems.de/toxoplasmen.pdf**

Mikrofilarien, Nematoden, Microfilaria, nematodes

Innes JR, Shoho C (1952, 1953), Fleming JO, Cook TD (2006), Correale J, Farez M (2007), Correale J, Farez M, Razzitte G (2008, 2009), Correale J, Farez M, Razzitte G (2008), Correale J, Farez M (2009), MacDonald A (2016)

- **Eosinophilie http://www.xerlebnishaft.de/eosinophilie.pdf**
- **Mikrofilarien http://www.xerlebnishaft.de/mikrofilarien.pdf**

Spirochaeten, spirochaeta

Buzzard EF (1911) Spirochetes in M.S. Lancet 11, 98
Bullock WE (now Gye) (1913) MS agent in Rabbits Lancet 1185
Steiner G (1917) Spirochetes The Cause of MS. Med Klin
Simmering (1918) Spirochetes in MS by Darkfield Micro
Steiner G (1918) Guinea Pig Inoculation with MS infectious agent from Human
Steiner G (1919) MS Agent Inoculation into Monkeys
Gye F (1921) MS Agent In Rabbits Brain 14, 213
Kaberlah (1922) MS Agent In Rabbits. Deutch Med Works
Sicard (1922) MS Spirochetes in Animal Model. Rev Neurol
Stepanopoulo (1922) Spirochetes in the CSF of MS Patients
Schlossman (1923) MS Agent in Animal Model. Rev Neuro
Blacklock (1924) MS Agent in Animals. Journal of Path and Bac
Wilson (1927) The Rat as A Carrier of MS. British Med Journal
Steiner G (1927) Understanding the Pathogenesis of MS
Steiner G (1928) Spirochetes in the Human Brain of MS Patients
Rogers, Helen J. (1932) The question of silver cells as proof of the spirochetal theory of disseminated sclerosis. J. Neurol. and Psychopathol. 13, 50
Simons (1933) Spirochetes in the CSF of MS Patients
Hassin (1939) Spirochete-like formations in MS
Adams (1948) Spirochetes within the Ventricle Fluid of Monkeys Inoculated from Human MS
Steiner G (1952) Acute plaques in MS and the role of spirochetes as etiology factor
Steiner G (1954) Morphology of Spirochaeta Myelophthora (Myelin Loving). MS Journal of Neuropathology and Exp Neurol 11:4 343
Steiner G (1954) Acute plaques in M.S., their pathogenetic significance and the role of spirochetes as the etiological factor. J. Neuropath. and Exp. Neur. 11:no 4:343, 1954
Ichelson R (1957) Cultivation of Spirochetes from Spinal Fluids of MS Cases with Negative Controls. Procl. Soc. Exp. Biol Med 70:411
Gay D Dick G (1986) Is multiple sclerosis caused by an oral spirochaete? Lancet (1986 Jul 12) 2(8498):75-7
Kurtz SK (1986) Relapsing fever/Lyme disease - Multiple sclerosis. Medical Hypotheses, volume 21, issue 3, pages 335-343
Marshall V (1988) Multiple sclerosis is a chronic central nervous system infection by a spirochetal agent. Med Hypotheses (1988 Feb) 25(2):89-92
Liegner (1990, 1992) Lyme encephalomyelitis and MS
Smielewska-Badora J (2000) Lyme borreliosis and Multiple sclerosis: Any Connection? A Seroepidemic study.
Fritzsche M (2004) Chronic Lyme borreliosis at the root of Multiple sclerosis - is a cure with antibiotics attainable?
… 2005 – 2018 see the listed literature below

Quelle: http://owndoc.com/lyme/multiple-sclerosis-is-lyme-disease-anatomy-of-a-cover-up/

Genetisches Risiko, genetic risc

Sawcer S, Hellenthal G, Pirinen **M et al. (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.** Nature. 2011 Aug 10; 476(7359): 214–219. doi: 10.1038/nature10251 PMCID: PMC3182531 EMSID: UKMS36028
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182531/

Hänninen A (2017) **Infections in MS: An innate immunity perspective.** Acta Neurol Scand. 136 Suppl 201, 10-14. doi: 10.1111/ane.12838. https://www.ncbi.nlm.nih.gov/pubmed/29068495
«Recent advances in our understanding of lymphatic drainage of CNS, its immune surveillance and effects of gut microbiota and obesity on systemic endotoxin levels and T-cell priming may open new perspectives to understanding the roles that infectious agents and microbes may have in MS. «

Immunmodulatoren im Frühstadium oder bei einem Krankheitsrückfall.
Immunomodulators in the early stages or in case of disease relapses.
Interferon-ß, Glatiramer acetate

Immunosuppression wenn Krankheitserreger sicher ausgeschlossen wurden.
Immunosuppression if pathogens are reliably excluded as a cause.

Bedenke die Risiken bei der Therapie mit Immunsuppressiva.
Consider the risks in therapy with immunosuppressants.

Havla J, Warnke C, Derfuss T et al (2016) **ÜBERSICHTSARBEIT. Interdisziplinäres Risiko-management in der Therapie der multiplen Sklerose.**
http://www.aerzteblatt.de/pdf/113/51/m879.pdf?ts=15.12.2016+13%3A42%3A47

Virusarten, viruses
Perron H (2000, 2009), Firouzi R (2003), Christensen T (2005), Levin LI (2005), Cossu D (2012), Djelilovic-Vranic J (2012), Tselis A (2012), Olival GS (2013), Mameli G (2013), Angelini DF (2013), Garcia-Montojo M (2013), Mancuso R, Saresella M (2013), García-Montojo M (2014), Sutherland S (2014), Mameli G (2014), Lossius A (2014), Mechelli R (2015), Campbell A (2017), Hassani A (2018), Pender MP (2018)
Bakterien, bacteria
Buzzard EF (1911), Bullock WE (now Gye) (1913), Steiner G (1917, 1918, 2019, 1927, 1928, 1952, 2x1954) Simmering (1918), Gye F (1921), Kaberlah (1922), Sicard (1922), Stepanopoulo (1922), Schlossman (1923), Blacklock (1924), Wilson (1927), Rogers, Helen J. (1932), Simons (1933), Hassin (1939), Adams (1948), Ichelson R (1957), Gay D (1986), Kurtz SK (1986), Marshall V (1988), Liegner (1990, 1992), Smielewska-Badora J (2000), Rostasy K, (2003), Fritzsche M (2004) Cossu D. (2012), Chen J (2016), Jangi S (2016), Barazin SE (2017, 2018), Tankou SK (2018), Kriesel JD (2019)
Protozoa
Kissler H (2001)
Nematodes
Innes JR (1952, 1953), Fleming JO (2006), Correale J (2007, 2008, 2009), MacDonald A (2016)

Marie P (1884) **Sclerose en plaque et maladies infectueuses**. Prog Med. 12, 287–289

Steiner G. (1931) **KRANKHEITSERREGER UND GEWEBSBEFUND BEI MULTIPLER SKLEROSE.** Springer. https://link.springer.com/content/pdf/bfm%3A978-3-662-28529-9%2F1.pdf

Steiner G (1952) **Acute plaques in MS**, **their pathogenetic significance and the role of spirochetes as the etiological factor**. J. Neuropath. Exp. Neur. 11(4), 343-372

INNES JR, SHOHO C (1952) **Nematodes, nervous disease, and neurotropic virus infection; observations in animal pathology of probable significance in medical neurology.** Br Med J. 2(4780), 366-8. PMID: 14944823 PMCID: PMC2021051
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2021051/

INNES JR, SHOHO C (1953) **Cerebrospinal nematodiasis: focal encephalomyelomalacia of animals caused by nematodes (Setaria digitata); a disease which may occur in man.** AMA Arch Neurol Psychiatry. 70(3), 325-49. PMID: 13079357 http://www.ncbi.nlm.nih.gov/pubmed/13079357

Steiner G (**1954**) Morphology of **Spirocheta Myelophtora** in MS. J. Neuropath. Exp. Neur. 13, 221-29

Ichelson R. (1957) **Cultivation of Spirochetes from Spinal Fluids of MS Cases with Negative Controls**. Procl. Soc. Exp. Biol Med 70, 411

Simons von HCR (1958) Is **Multiple sclerosis a spirochaetosis**? Dt. Med. Wschr. 83, 1196-1200

Martin A, Younge EL, Kost PF (1959) The occurrence of **Spirocheta Myelophtora** in cerebrospinal fluid. Proc. Penn. Acad. Sci. 33, 55-93

Ustimenko T (1965) L-Forms of **Treponema pertenue**. Vestn.Akad. Med. Nauk.SSSR,20, 46-50

Kurtzke JF, Hyllested K (1979) **Multiple sclerosis in the Faroe Islands: I. Clinical and epidemiological features.** Annals of neurology. 5(1), 6–21, doi:10.1002/ana.410050104. PMID 371519. http://www.ncbi.nlm.nih.gov/pubmed/371519
« We conclude that there was an epidemic of MS on the Faroes and that the disease was probably introduced by the British troops (or their baggage). If so, then MS on the Faroes is a transmissible disease, most likely infectious; but only about 1 in 500 of the exposed individuals were clinically affected. »

Gay D, Dick G (1986) Is **multiple sclerosis** caused by an **oral spirochaete?** Lancet (1986 Jul 12) 2(8498), 75-7 http://www.ncbi.nlm.nih.gov/pubmed/2873382

Gay D, Dick G (1986) **Spirochetes, Lyme disease and multiple sclerosis**. Lancet. 685

Ibrahim MZM (1986) **On the etiology of MS**, new observations? Abst Anat. Rec. 214A, 58

Kurtz SK (1986) **Relapsing fever/Lyme disease – Multiple sclerosis**. Medical Hypotheses, volume 21, issue 3, pages 335-343
http://www.unboundmedicine.com/medline/citation/3642202/Relapsing_fever/Lyme_disease__Multiple_sclerosis_

Dick G., Gay D (1988) Multiple sclerosis – **autoimmune or microbial**? A critical review with additional observations. J. Infect. 16, 25-35

Marshall V (1988) Multiple sclerosis is a chronic central nervous system infection by a **spirochetal agent**. Med Hypotheses (1988 Feb) 25(2), 89-92 http://www.ncbi.nlm.nih.gov/pubmed/3357458

Stechenberg BW (1988) Lyme disease: the latest **great imitator**. Pediatr Infect Dis J 7, 402

Pachner AR (1989) Neurologic manifestations of Lyme disease, the new "**great imitator**". Rev Infect Dis S1482-6. Abstract

Ellison GW (1989) Multiple Sclerosis: why? Biomed & Pharmacother 43, 327-333.

Halperin JJ, Luft BJ, Anand AK, et al. (1989) **Lyme neuroborreliosis**: central nervous system manifestations. Neurology 39(6), 753-9. Abstract

Liegner KB. (1990) Evidence for a borrelial etiology and pathogenesis in a series of patients carrying a diagnosis of multiple sclerosis. (abstract). International Northwestern Conference on Diseases in Nature Communicable to Man. Hamilton, MT.

Heller J, Holzer G, Schimrigk K (1990) Immunological differentiation between **neuroborreliosis and multiple sclerosis**. J Neurol 237(8), 465-70. Abstract

Heller J, Holzer G, Schimrigk K (1990) ELISA for specifying oligoclonal bands of isoelectric focusing of cerebrospinal fluid in patients with **neuroborreliosis and multiple sclerosis**. Nervenarzt 61(4), 248-9. Full Citation

Halperin JJ, Kaplan GP, Brazinsky S et al. (1990) Immunological reactivity against B. burgdorferi in patients with motor neuron disease. Arch Neurol. 47, 568-594 http://www.ncbi.nlm.nih.gov/pubmed/2334308

Halperin JJ, Volkman DJ, Wu P (1991) Central nervous system abnormalities in **Lyme neuroborreliosis**. Neurology 41(10), 1571-82. Abstract

Felgenhauer K, Reiber HO (1991) **Die MS-charakteristischen Liquorveränderungen als diagnostische Hilfe bei der enzephalitischen Form der multiplen Sklerose.** Multiple Sklerose

Neuroonkologie Konstitutionelle Dyslexie Volume 6 of the series Verhandlungen der Deutschen Gesellschaft für Neurologie pp 155-156

Murray R, Morawetz R, Kepes J, et al. (1992) **Lyme neuroborreliosis** manifesting as an intracranial mass lesion. Neurosurgery 30(5), 769-73. Abstract

Liegner KB (1992) Evidence for borrelial etiology and pathogenesis in a series of patients carrying a diagnosis of multiple sclerosis [abstract]. 45th International Northwestern Conference on Diseases in Nature Communicable to Man. Vancover, British Columbia.

Liegner KB (1992) Difficulty of distinction between borrelial (Lyme) encephalomyelitis and multiple sclerosis [abstract]. 45th International Northwestern Conference on Diseases in Nature Communicable to Man. Vancover, British Columbia.

KurtzkeJF et al. (1993) **Multiple sclerosis in the Faroe Islands. 5. The occurrence of the fourth epidemic as validation of transmission**. Acta neurologica Scandinavica. 88(3), 161–173, PMID 8256551. http://www.ncbi.nlm.nih.gov/pubmed/8256551
«The existence of epidemic IV within the F4 cohort of Faroese may be taken as validation of our transmission models and of our theses as to the nature of multiple sclerosis. «

Kurtzke JF (1993) **Epidemiologic evidence for multiple sclerosis as an infection.** Clin Microbiol Rev. 6, 382–427. [PMC free article] [PubMed]

Coyle PK, Krupp LB et al. (1993) **Significance of reactive Lyme serologv in multiple sclerosis**. Ann. Neurol. 34 (5), 745-747.

Haegert DG Marrosu MG (1994) **Genetic susceptibility** to multiple sclerosis. Ann Neurol., Suppl 2, 36, 204-210

Lana-Peixoto MA (1994) **Multiple sclerosis and positive Lyme serology**. Arq Neuropsiquiatr 52(4), 566-71. Abstract

Poser CM (1994) The epidemiology of multiple sclerosis: a general overview. Ann Neurol. 36, 180–189. [PubMed]

Puccioni-Sohler M, Kitze B, Felgenhauer K, Graef IT, Lange P, Novis S et al. (1995) **The value of CSF analysis for the differential diagnosis of HTLV-1 associated myelopathy and multiple sclerosis.** Arq Neuropsychiatr. 53(4), 760-5. doi:10.1590/S0004-282X1995000500008

Gale CR, Martyn CN (1995) **Migrant studies in multiple sclerosis. Progress in neurobiology**. 47(4–5), 425–448, PMID 8966212. (Übersichtsarbeit). http://www.ncbi.nlm.nih.gov/pubmed/8966212
« Migrant studies add little to our understanding of the genetics of multiple sclerosis but they emphasise the importance of environmental factors. We discuss several possible interpretations of the patterns seen in migrant studies, including the hypothesis that multiple sclerosis is a sequel to delayed exposure to a common infectious agent. One candidate for such an infectious agent is Epstein-Barr virus.“

Curless RG, Schatz NJ, Bowen BC, et al. (1996) **Lyme neuroborreliosis masquerading as a brainstem tumor in a 15-year-old.** Pediatr Neurol 15(3), 258-60. Abstract

Reiber H, Ungefehr St, Jacobi Chr. (1998) **The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis.** Mult Scler. 4(3), 111-7. doi:10.1177/135245859800400304

Chmielewska-Badora J, Cisak E, Dutkiewicz J. (2000) **Lyme borreliosis and Multiple sclerosis: Any Connection? A Seroepidemic study.** Ann Agric Environ Med. issue 7, 141-143 http://www.ncbi.nlm.nih.gov/pubmed/11153045

Perron H, Perin JP, Rieger F, Alliel PM (2000) **Particle-associated retroviral RNA and tandem RGH/HERV-W copies on human chromosome 7q: possible components of a 'chain-reaction' triggered by infectious agents in multiple sclerosis?** J Neurovirol. 6 Suppl 2, S67-75.

Christensen T, Sørensen PD, Hansen HJ, Møller-Larsen A. (2001) **Endogenous retroviruses** in multiple sclerosis. Ugeskr Laeger. 163(3), 297-301.

Brorson O, Brorson SH, Henriksen TH, Skogen PR, Schøyen R. (2001) **Association between Multiple sclerosis and Cystic Structures in Cerebrospinal Fluid**. Infection 29(6), 315-319 http://www.ncbi.nlm.nih.gov/pubmed/11787831

Kissler H. (2001) **Is Multiple Sclerosis caused by a silent infection with malarial parasites?** Med Hypotheses 57, 292-301

Schmutzhard E (2002) **Multiple sclerosis and Lyme borreliosis**. Wien Klin Wochenschr 114 (13-14), 539-43. Abstract
http://emerge.org.au/wp-content/uploads/2015/11/Schmutzhard-E.-Multiple-sclerosis-and-Lyme-borreliosis.-Wien.-Klin.-Wochenschr.-2002-11413-14-539-543.pdf

Neidigh JW, Fesinmeyer RM, Andersen NH (2002) **Designing a 20-residue protein.** Nat. Struct. Biol. 9, 425–430. [CrossRef] [PubMed]

Markus Fritzsch (2002) **Geographical and seasonal correlation of multiple sclerosis to sporadic schizophrenia.** Int J Health Geogr. 1, 5. doi: 10.1186/1476-072X-1-5 PMCID: PMC149400
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC149400/

Hawkes CH (2002) **Is multiple sclerosis a sexually transmitted infection?** J Neurol Neurosurg Psychiatry. 73, 439–443. [PMC free article] [PubMed]

Firouzi R, Rolland A, Michel M, (2003) Multiple sclerosis-associated **retrovirus particles** cause T lymphocyte-dependent death with brain hemorrhage in humanized SCID mice model. J Neurovirol. 9(1), 79-93 http://www.ncbi.nlm.nih.gov/pubmed/12587071

Rostasy K, Reiber H, Pohl D et al. (2003) **Chlamydia pneumoniae in children with MS: Frequency and quantity of intrathecal antibodies.** Neurology 61, 125-128
http://www.ncbi.nlm.nih.gov/pubmed/12847174

Metz LM, Zhang Y, Yeung M et al. (2004) **Minocycline Reduces Gadolinium-Enhancing Magnetic Resonance Imaging Lesions in Multiple Sclerosis.** American Neurological Association. Published by Wiley-Liss, Inc., through Wiley Subscription Services.
http://owndoc.com/pdf/MS-lesions-minocycline.pdf

Fritzsche M (2005) **Chronic Lyme borreliosis at the root of multiple sclerosis--is a cure with antibiotics attainable?** Med Hypotheses. 64(3), 438-48
http://www.ncbi.nlm.nih.gov/pubmed/15617845
http://www.lymepa.org/Chronic_Lyme_borreliosis_at_the_root_of_Multiple_Sclerosis_and_a_possible_cure_with_antibiotics.pdf

Bednárová J, Stourac P, Adam P (2005) **Relevance of immunological variables in neuroborreliosis and multiple sclerosis**. Acta Neurol Scand 112(2), 97-102. Abstract

Christensen T. (2005) Association of **human endogenous retroviruses** with multiple sclerosis and possible interactions with herpes viruses. Rev Med Virol. 15(3), 179-211.

Levin LI et. al. (2005) **Temporal Relationship Between Elevation of Epstein-Barr Virus Titers and Initial Onset of Neurologic Symptoms in Multiple Sclerosis**. JAMA 293, 2496-2500.

Fleming JO, Cook TD (2006) **Multiple sclerosis and the hygiene hypothesis.** Neurology. 67, 2085–2086. Crossref PubMed | Scopus (86)

Drozdowski W (2006) **Multifocal central nervous system lesions -- multiple sclerosis or neuroborreliosis?**. Przegl Epidemiol 39-45. Abstract

Adam P, Sobeka O, Scott CS (2007) **Analysis of cerebrospinal fluid cell populations with monoclonal antibodies.** Folia Microbiol (Praha) 52(5), 529-34. Abstract

Fadil H, Kelley RE, Gonzalez-Toledo E (2007) **Differential diagnosis of multiple sclerosis**. Int Rev Neurobiol 393-422. Abstract

Perczel A, Hudáky P, Pálfi, VK (2007) **Dead-end street of protein folding: Thermodynamic rationale of amyloid fibril formation.** J. Am. Chem. Soc. 129, 14959–14965. [CrossRef] [PubMed]

Batinac T, Petranovic D, Zamolo G, et al. (2007) **Lyme borreliosis and multiple sclerosis are associated with primary effusion lymphoma.** Med Hypotheses 69(1), 117-9. Abstract

Correale J, Farez M (2007) **Association between parasite infection and immune responses in multiple sclerosis.** Ann Neurol. 61, 97–108. Crossref | PubMed | Scopus (235)

Correale J, Farez M, Razzitte G (2008) **Helminth infections associated with multiple sclerosis induce regulatory B cells.** Ann Neurol. 64, 187–199.

Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH (2008) **Differential diagnosis of suspected multiple sclerosis: a consensus approach.** Mult Scler. 14(9), 1157–1174 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850590/

Somers V, Govarts C, Somers K et al. (2008) **Autoantibody Profiling in Multiple Sclerosis Reveals Novel Antigenic Candidates.** The Journal of Immunology. 180, 3957-3963 http://www.jimmunol.org/content/180/6/3957.full.html

Correale J, Farez M (2009) **Helminth antigens modulate immune responses in cells from multiple sclerosis patients through TLR2-dependent mechanisms**. J Immunol. 83, 5999–6012. Crossref | PubMed | Scopus (66)

Berghoff W (2009) **Differentialdiagnose Multiple Sklerose (MS) / Lyme-Neuroborreliose (LNB)** http://www.praxis-berghoff.de/dokumente/Differentialdiagnose_MS_LNB.pdf

Reiber H, Teut M, Pohl D, Rostasy KM, Hanefeld F. (2009) **Paediatric and adult multiple sclerosis: age related differences and time course of the neuroimmunological response in cerebrospinal fluid.** Multiple Scler. 15(12), 1466-80. doi:10.1177/1352458509348418

Liegner KB (2009) **Lyme Neuroborreliosis(LNB) vs. multiple sclerosis(MS): problematic differentiation** ILADS BREAK-OUT SESSION GAYLORD NATIONAL CONVENTION CENTER NATIONAL HARBOR, MARYLAND October 24-25, 2009 https://groups.yahoo.com/neo/groups/ILADS/attachments/855121410;_ylc=X3oDMTJxNHIzN3BzBF9TAzk3MzU5NzE0BGdycElkAzI5MjM5NzkEZ3Jwc3BJZAMxNzA1MDgzMDk4BHNlYwNhdHRhY2htZW50BHNsawN2aWV3T25XZWIEc3RpbWUDMTQ2OTM1NzU3OA--

Radulescu A, Tatulescu D, Perju-Dombrava L et al. (2009) **Controversies in late Neuroborreliosis and Multiple sclerosis – case series.** Therapeutics, Pharmacology and Clinical Toxicology. XIII(1), 57-62 http://pdf5.net/c/controversies-in-late-neuroborreliosis-and-multiple-sclerosis-case-w6497-pdf.pdf https://www.google.de/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0ahUKEwjUxaihpvzVAhXLVxQKHXpOAm0QFggtMAA&url=http%3A%2F%2Fwww.mms-seminar.com%2Fwp-content%2Fuploads%2F2015%2F08%2F2009-romanian-study-ms-is-lyme.pdf&usg=AFQjCNGW4fKsiu5UZiwtGHQLDPiA_ozQUQ

« The diagnosis of MS and NB are diffi cult because of remarkably similar clinical and neuroimaging features. Th e infectious etiology of MS remains probable and in patients diagnosed with possible MS it is reasonable to evaluate B. burgdorferi infection in order to ensure etiologic treatment. »

Perron H, Bernard C, Bertrand JB et al. (2009) **Endogenous retroviral genes, Herpesviruses and gender** in Multiple Sclerosis. J Neurol Sci. 286(1-2), 65-72.

Blanc F, Ballonzoli L, Marcel C et al. (2010) **Lyme optic neuritis**.J Neurol Sci 295(1-2), 117-9 Abstract

Carulla N, Zhou M, Giralt E et al. (2010) **Structure and intermolecular dynamics**

of aggregates populated during amyloid fibril formation studied by hydrogen/deuterium exchange. Acc. Chem. Res. 43, 1072–1079. [CrossRef] [PubMed]

Lauer K (2010) **Environmental risk factors in multiple sclerosis.** Expert Rev Neurother. 10(3), 421-40. doi: 10.1586/ern.10.7. http://www.ncbi.nlm.nih.gov/pubmed/20187864

Mattsson N, Bremell D, Anckarsäter R, et al. (2010) **Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism.** BMC Neurol 51. Abstract

Brinar VV, Habek M. (2010) **Rare infections mimicking MS.** Clin Neurol Neurosurg. 112(7), 625-8. doi: 10.1016/j.clineuro.2010.04.011. Epub 2010 May 2.http://www.ncbi.nlm.nih.gov/pubmed/20439131

Nørgaard M, Nielsen RB, Jacobsen JB, Gradus JL, Stenager E, Koch-Henriksen N, Lash TL, Sørensen HAT (2011) **Use of penicillin and other antibiotics and risk of multiple sclerosis: a population-based case-control study.** Am J Epidemiol. 174(8), 5-8. doi: 10.1093/aje/kwr201. Epub http://aje.oxfordjournals.org/content/174/8/945

Spirin NN, Baranova NS, Fadeeva OA, et al. (2011) **Differential aspects of multiple sclerosis and chronic borrelial encephalomyelitis**. Zh Nevrol Psikhiatr Im S S Korsakova 111(7), 8-12. Abstract

Krumbholz M, Derfuss T, Hohlfeld R, Meinl E (2012) **B cells and antibodies in multiple sclerosis pathogenesis and therapy.** Nat. Rev. Neurol. 8, 613-623 http://www.ncbi.nlm.nih.gov/pubmed/23045237

Cossu D, Masala S, Cocco E et al. (2012) **Are Mycobacterium avium subsp. paratuberculosis and Epstein-Barr virus triggers of multiple sclerosis in Sardinia?** Mult Scler. 18(8), 1181-4. doi: 10.1177/1352458511433430. Epub 2012 Jan 19. http://www.ncbi.nlm.nih.gov/pubmed/22261119

Djelilovic-Vranic J, Alajbegovic A. (2012) **Role of early viral infections in development of multiple sclerosis.** Med Arh. 66(3 Suppl 1), 37-40.

Comabella M, Khoury SJ (2012) **Immunopathogenesis of multiple sclerosis.** Clinical immunology (Orlando, Fla.)

Tselis A (2012) **Epstein-Barr virus cause of multiple sclerosis.** Curr Opin Rheumatol. 24(4), 424-8. doi: 10.1097/BOR.0b013e3283542cf8. https://www.ncbi.nlm.nih.gov/pubmed/22617821

Olival GS, Lima BM, Sumita LM, Serafim V, Fink MC, Nali LH et al. (2013) **Multiple sclerosis and herpes virus interaction.** Arq Neuropsiquiatr. 71(9B), 727-30. doi:10.1590/0004-282X20130160

Zajicek J (2013) **Multiple sclerosis.** Handbook of clinical neurology 2013

Rocha AJ, Littig IA, Nunes RH, Tilbery CP. (2013) **Central nervous system infectious diseases mimicking multiple sclerosis, recognizing distinguishable features using MRI.** Arq Neuropsiquiatr. 71(9B), 738-46. doi:10.1590/0004-282X20130162
https://www.ncbi.nlm.nih.gov/pubmed/24141516
http://www.scielo.br/pdf/anp/v71n9B/0004-282X-anp-71-09b-738.pdf

Mameli G, Madeddu G, Mei A et al. (2013) **Activation of MSRV-Type Endogenous Retroviruses** during Infectious Mononucleosis and **Epstein-Barr Virus Latency**: The Missing Link with Multiple Sclerosis? PLoS One. 8(11), e78474. doi: 10.1371/journal.pone.0078474.
http://www.ncbi.nlm.nih.gov/pubmed/24236019
"Thus, the data indicate that the two main links between EBV and MS (IM and high anti-EBNA-1-IgG titers) are paralleled by activation of the potentially neuropathogenic HERV-W/MSRV. These novel findings suggest HERV-W/MSRV activation as the missing link between EBV and MS, and may open new avenues of intervention."

Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, Ruggieri S, Gasperini C, Buttari F, Centonze D, Mechelli R, Salvetti M, Borsellino G, Aloisi F, Battistini L (2013) Increased CD8+ T cell response to **Epstein-Barr virus lytic antigens** in the active phase of multiple sclerosis. PLoS Pathog. 9(4), e1003220. doi: 10.1371/journal.ppat.1003220. http://www.ncbi.nlm.nih.gov/pubmed/23592979

Garcia-Montojo M, Dominguez-Mozo M, Arias-Leal A et al. (2013) **The DNA copy number of human endogenous retrovirus-W (MSRV-type) is increased in multiple sclerosis patients and is influenced by gender and disease severity.** PLoS One. 8(1), e53623. doi: 10.1371/journal.pone.0053623. http://www.ncbi.nlm.nih.gov/pubmed/23308264
"MSRV increases its copy number in PBMC of MS patients and particularly in women with high clinical scores. This may explain causes underlying the higher prevalence of MS in women. The association with the clinical severity calls for further investigations on MSRV load in PBMCs as a biomarker for MS."

Mancuso R, Saresella M, Hernis A, Agostini S, Piancone F, Caputo D, Maggi F, Clerici M. (2013) **Torque teno virus (TTV) in multiple sclerosis patients with different patterns of disease.** J Med Virol. 85(12), 2176-83. doi: 10.1002/jmv.23707. Epub 2013 Aug 19.

Ascherio A (2013) **Environmental factors in multiple sclerosis: Expert review of neurotherapeutics.** 13(12) Suppl, 3–9, doi:10.1586/14737175.2013.865866. PMID 24289836. (Review). http://www.tandfonline.com/doi/abs/10.1586/14737175.2013.865866#.V5RpYY9OKM8

García-Montojo M, de la Hera B, Varadé J, et al. (2014) **HERV-W polymorphism in chromosome X is associated with multiple sclerosis risk and with differential expression of MSRV.** Retrovirology. 11(1), 2. http://www.ncbi.nlm.nih.gov/pubmed/24405691

Sutherland S (2014) **Remyelination: Are Exosomes Containing microRNA the Answer? Naturally produced exosomes with miRNA led to increased myelination in vitro and in vivo.** New Findings | 13 Feb 2014
http://www.msdiscovery.org/news/new_findings/9751-remyelination-are-exosomes-containing-microrna-answer

Mameli G, Cossu D, Cocco E et al. (2014) **Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis** peptides are cross recognized by anti-myelin basic protein antibodies in **multiple sclerosis patients**. J Neuroimmunol. pii: S0165-5728(14)00063-0. doi: 10.1016/j.jneuroim.2014.02.013. http://www.ncbi.nlm.nih.gov/pubmed/24642384

Shimizu F, Tasaki A, Sano Y, Ju M, Nishihara H, Oishi M, Koga M, Kawai M, Kanda T (2014) **Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.** PLoS One. 9(3), e92872. Epub 2014 Mar 31. PMID: 24686948. Abstract

Berghoff W (2014) **Differentialdiagnose Multiple Sklerose (MS) / Lyme-Neuroborreliose (LNB).**
http://www.praxis-berghoff.de/dokumente/berghoff150714/Kapitel_14_Differentialdiagnose_MS_LNB.pdf

Beltrán E, Obermeier B, Moser M et al. (2014) **Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation.** Brain : a journal of neurology 07/2014; DOI: 10.1093/brain/awu205 Source: PubMed http://www.ncbi.nlm.nih.gov/pubmed/25060097
„Our data suggest that the intrathecal milieu sustains a **germinal centre**-like reaction with clonal expansion and extensive accumulation of somatic hypermutation in IgM-producing B cells.
Unsere Daten deuten darauf hin, dass das intrathekale Milieu eine **Keimzentrums-ähnliche** Reaktion enthält mit klonaler Expansion und umfangreicher Hypermutation in IgM-produzierenden B-Zellen".

Lossius A, Johansen JN, Vartdal F, Robins H, Benth JS, Holmøy T, Olweus J. (2014) **High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8+ T cells.** Eur J Immunol. doi: 10.1002/eji.201444662.
http://www.ncbi.nlm.nih.gov/pubmed/25103993

Villar LM, Picón C, Costa-Frossard L et al. (2014) **Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.** DOI: 10.1111/ene.12579
European Journal of Neurology http://onlinelibrary.wiley.com/doi/10.1111/ene.12579/abstract

Multiple Sclerosis and Lyme Pathology Research Fund (2014) http://www.lyme-ms-pathology.com/

De Bock L, Somers K, Fraussen J et al. (2014) **Sperm-Associated Antigen 16 Is a Novel Target of the Humoral Autoimmune Response in Multiple Sclerosis.** The Journal of Immunology 193, 2147-2156
http://www.researchgate.net/publication/264430600_Sperm-Associated_Antigen_16_Is_a_Novel_Target_of_the_Humoral_Autoimmune_Response_in_Multiple_Sclerosis

Le Houézec D (2014) **Evolution of multiple sclerosis in France since the beginning of hepatitis B vaccination.** Immunol Res. 60(2-3), 219-25. doi: 10.1007/s12026-014-8574-4.
http://www.ncbi.nlm.nih.gov/pubmed/25395338 http://link.springer.com/article/10.1007%2Fs12026-014-8574-4#page-1
http://healthimpactnews.com/2014/new-study-hepatitis-b-vaccination-in-france-sparked-a-wave-of-new-cases-of-ms/
« The application of the Hill's criteria to these data indicates that the correlation between hepatitis B vaccine and multiple sclerosis may be causal. »

Mechelli R, Manzari C, Policano C (2015) **Epstein-Barr virus genetic variants are associated with multiple sclerosis.** Neurology. pii: 10.1212/WNL.0000000000001420. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/25740864
« Our study unveils a strong association between Epstein-Barr virus genomic variants and MS, reinforcing the idea that Epstein-Barr virus contributes to disease development. »

Márquez AC, Horwitz MS (2015) **The Role of Latently Infected B Cells in CNS Autoimmunity.** Front Immunol. 6, 544. doi: 10.3389/fimmu.2015.00544. eCollection 2015.
http://www.ncbi.nlm.nih.gov/pubmed/26579121

Álvarez-Cermeño JC, Villar LM (2015) **Genetic variability affects CNS IgG production in MS**. nature reviews | Neurology. doi:10.1038/nrneurol.2015.55 Published online XX Month 2015
http://www.researchgate.net/publication/274966753_Multiple_sclerosis_Genetic_variability_affects_CNS_IgG_production_in_MS

Rodríguez-Martín E, Picón C, Costa-Frossard L, Alenda R et al (2015) **Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis.** Clin Exp Immunol. 180(2), 243-9. doi: 10.1111/cei.12580. http://www.ncbi.nlm.nih.gov/pubmed/25565222

Ziemssen T, Derfuss T, de Stefano N et al. (2015) **Optimizing treatment success in multiple sclerosis.** J Neurol. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26705122

Multiple Sclerosis Risk (2015) **Environmental risk factors and medical conditions associated with Multiple Sclerosis** http://www.polygenicpathways.co.uk/msrisk.htm

Wekerle H (2015) **Nature plus nurture: the triggering of multiple sclerosis.** Swiss Med Wkly. 145, w14189. doi: 10.4414/smw.2015.14189. http://www.ncbi.nlm.nih.gov/pubmed/26430854
« New experimental data indicate that the actual trigger of this attack is however provided by an interaction of brain-specific immune cells with components of the regular commensal gut flora, the intestinal microbiota. This concept opens the way for new therapeutic approaches involving modulation of the microbiota by dietary or antibiotic regimens «.

Reiber H, Kruse-Sauter H, Quentin C (2015) **Antibody patterns vary arbitrarily between cerebrospinal fluid and aqueous humor of the individual multiple sclerosis patient: specificity-independent pathological B cell function.** J Neuroimmunol. 278, 247-54. doi:10.1016/j.jneuroim.2014.11.013

Claes N, Fraussen J, Stinissen P et al. (2015) **B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions.** Front Immunol. 6, 642. Published online doi: 10.3389/fimmu.2015.00642 PMCID: PMC4685142
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685142/

Tremlett H, Fadrosh DW, Faruqi AA et al. (2016) **Gut microbiota in early pediatric multiple sclerosis: a case-control study.** Eur J Neurol. doi: 10.1111/ene.13026. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/27176462
«In recent onset pediatric MS, perturbations in the gut microbiome composition were observed, in parallel with predicted enrichment of metabolic pathways associated with neurodegeneration. Findings were suggestive of a pro-inflammatory milieu. « -> http://www.kabilahsystems.de/probiotika.pdf

MacDonald A (2016) **London Lecture May 15 2016** https://vimeo.com/166688480
« Multiple Sclerosis is a Neural Larval Migrans Illness. … Spirochetes Reside INSIDE of the Worms {Endisymbiont Borrelia} … DNA transfer between Borrelia and the worm. The endosymbiont RELEASE From The Worm when the Worm dies.»

MacDonald A (2016) **Nematode filarial Worms in cerebrospinal fluid of a Multiple Sclerosis patient at autopsy** [version 1; not peer reviewed]. F1000Research 79 (poster) (doi: 10.7490/f1000research.1111264.1)

Havla J, Warnke C, Derfuss T et al. (2016) **Interdisziplinäres Risikomanagement in der Therapie der multiplen Sklerose.** Deutsch Arztebl Int 113, 879-86 Doi:10.3238/arztebl.2016.0879
„Die verbesserte Wirksamkeit der MS-Therapie geht mit erhöhten Risiken der unnerwünschten Arzneimittelwirkungen (UAW), die ein interdisziplinäres Risikomanagement erfordern, einher“

Chen J et al. (2016) **Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls**. Sci Rep 6, 28484.
https://www.researchgate.net/publication/304535968_Multiple_sclerosis_patients_have_a_distinct_gut_microbiota_compared_to_healthy_controls

Jangi S et al. (2016) **Alterations of the human gut microbiome in multiple sclerosis**. Nat Commun 7, 12015.
https://www.researchgate.net/publication/304539080_ARTICLE_Alterations_of_the_human_gut_microbiome_in_multiple_sclerosis

Barazin SE et al. (2017) **The MS-Associated Gut Microbiome**.
https://www.researchgate.net/publication/316237673_The_MS-Associated_Gut_Microbiome

Beridze M, Khizanishvili N, Mdivani M et al. (2017) **UNUSUAL MANIFESTATION OF NEUROBORELIOSIS (CASE REPORT).** Georgian Med News. (264), 72-75.
https://www.ncbi.nlm.nih.gov/pubmed/28480854
„MS and even Parkinsonism in suspicious cases should thoroughly be investigated for differentiation from chronic Neuroboreliosis.“

Campbell A, Hogestyn JM, Folts ChrJ et al. (2017) **Expression of the Human Herpesvirus 6A Latency-Associated Transcript U94A Disrupts Human Oligodendrocyte Progenitor Migration**. Scientific Reports, 7 (1) DOI: 10.1038/s41598-017-04432-y

Tankou SK et al. (2018) **Investigation of probiotics in multiple sclerosis**. Mult Scler 24, 58-63.
https://www.researchgate.net/publication/322333353_Investigation_of_probiotics_in_multiple_sclerosis

Hassani A, Corboy JR, Al-Salam S, Khan G (2018) **Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells.** PLoS One. 13(2), e0192109. doi: 10.1371/journal.pone.0192109. eCollection 2018.
https://www.ncbi.nlm.nih.gov/pubmed/29394264
«To the best of our knowledge, this is the most comprehensive study demonstrating that EBV is present and transcriptionally active in the brain of most cases of MS and supports a role for the virus in MS pathogenesis. «

Barazani S (2018) **Looking for a trigger in multiple sclerosis: Is it in the gut?** DOI10.13140/RG.2.2.16127.92323. Projects Microbiome in multiple sclerosis
https://www.researchgate.net/publication/323129479_Looking_for_a_trigger_in_multiple_sclerosis_Is_it_in_the_gut

Planas R, Santos R, Tomas-Ojer P et al. (2018) **GDP-l-fucose synthase is a CD4$^+$ T cell-specific autoantigen in DRB3*02:02 patients with multiple sclerosis.** Sci Transl Med. 10(462). pii: eaat4301. doi: 10.1126/scitranslmed.aat4301. https://www.ncbi.nlm.nih.gov/pubmed/30305453
« By using a brain-infiltrating CD4$^+$ T cell clone that is clonally expanded in multiple sclerosis brain lesions and a systematic approach for the identification of its target antigens, positional scanning peptide libraries in combination with biometrical analysis, we have identified guanosine diphosphate (GDP)-l-fucose synthase as an autoantigen that is recognized by cerebrospinal fluid-infiltrating CD4$^+$ T cells from HLA-DRB3*-positive patients. Significant associations were found between reactivity to GDP-l-fucose synthase peptides and DRB3*02:02 expression, along with reactivity against an immunodominant myelin basic protein peptide. These results, coupled with the cross-recognition of homologous peptides from gut microbiota, suggest a possible role of this antigen as an inducer or driver of pathogenic autoimmune responses in multiple sclerosis. »

Pender MP, Csurhes PA, Smith C et al. (2018) **Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis.** JCI Insight. 3(22). pii: 124714. doi: 10.1172/jci.insight.124714. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/30429369

„Further clinical trials are warranted to determine the efficacy of EBV-specific T cell therapy in MS."

Kriesel JD, Bhetariya P, Wang ZM, Renner D, Palmer C, Fischer KF (2019) **Spectrum of Microbial Sequences and a Bacterial Cell Wall Antigen in Primary Demyelination Brain Specimens Obtained from Living Patients.** Sci Rep. 9(1), 1387. doi: 10.1038/s41598-018-38198-8.
„ Human gene expression analysis showed increased expression of inflammation-related pathways in the MS group. This data shows that demyelinating brain lesions are associated with the presence of microbial RNA sequences and bacterial antigen. This suggests that MS is triggered by the presence of a diverse set of microbes within a lesion. »

Brown JWL et al. (2019) **Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.** JAMA. 321(2), 175-187. doi: 10.1001/jama.2018.20588. https://www.ncbi.nlm.nih.gov/pubmed/30644981 https://www.researchgate.net/publication/330405211_Association_of_Initial_Disease-Modifying_Therapy_With_Later_Conversion_to_Secondary_Progressive_Multiple_Sclerosis

Berghoff W (2014) **Differentialdiagnose Multiple Sklerose (MS) / Lyme-Neuroborreliose (LNB)** http://www.praxis-berghoff.de/dokumente/berghoff150714/Kapitel_14_Differentialdiagnose_MS_LNB.pdf

Kolber P, Luessi F, Meuth SG et al. (2015) **Aktuelles zur Therapieumstellung bei Multipler Sklerose.** Der Nervenarzt http://link.springer.com/article/10.1007%2Fs00115-015-4368-8

Higleras Y, Jimenez-Martin I, Munoz L et al. (2016) **Características clínicas del deterioro cognitivo en la demencia por esclerosis múltiple: estudio transversal.** https://www.researchgate.net/publication/298971174_Demecia_en_Esclerosis_Multiple

- (2016) **„Qualitätshandbuch Multiple Sklerose"** Empfehlungen zur Therapie der MS für Ärzte Schmidt RM, Hoffmann F, Faiss JH, Köhler W, Zettl UK (2017) **Multiple Sklerose**. 7. Auflage, 544 Seiten, 83 Farbabbildungen, kartoniert.

- URTEIL DES GERICHTSHOFS (Zweite Kammer) (21. Juni 2017) „Vorlage zur Vorabentscheidung – Richtlinie 85/374/EWG – Haftung für fehlerhafte Produkte – Art. 4 – Arzneimittelhersteller **– Impfstoff gegen Hepatitis B – Multiple Sklerose –** http://curia.europa.eu/juris/document/document.jsf?text=&docid=192054&pageIndex=0&doclang=DE&mode=req&dir=&occ=first&part=1&cid=835102/ **[S.a. Le Houézec D (2014)]**

- Montalban X, Gold R, Thompson AJ et al. (2018) **ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.** Multiple Sclerosis Journal. http://journals.sagepub.com/doi/full/10.1177/1352458517751049

- (2018) **European Medicines Agency. EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders.** 2 March 2018. EMA/120379/2018. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/03/news_detail_002917.jsp&mWC0b01ac058004d5c1

Liste von Multiple-Sklerose-Wirkstoffen in der Erprobung und bei V.a. Infektion
Multiple sclerosis drugs in research and for suspected infection
https://de.wikipedia.org/wiki/Liste_von_Multiple-Sklerose-Wirkstoffen_in_der_Erprobung
https://en.wikipedia.org/wiki/Multiple_sclerosis_research

Immunstimulantien, immune restauration, immune stimulation
http://www.kabilahsystems.de/immunsti.pdf

Isoprinosine, Delimmun®
"**Inosine: Inosine is a compound that has shown interesting preliminary results in phases I and II clinical trials.[31][32] Two different mechanisms of action have been proposed. First, it produces uric acid after ingestion,[33] which is a natural antioxidant;[34] second, it has been shown to induce axonal rewiring in laboratory animals with stroke,[35] and spinal cord injury.[36] However it can cause health problems in a long-term treatment,[37] mainly kidney stones.[38] It seems that its mechanism of action is peroxynitrite inactivation[39] Other reports point to an immune modulation[40]**"
Bibliographical reference: https://en.wikipedia.org/wiki/Multiple_sclerosis_research

Plemel JR (2018) **Three new avenues to treat progressive Multiple Sclerosis: remyelination, neuroprotection, and targeting astrocytes.**
https://www.researchgate.net/blog/post/three-new-avenues-to-treat-progressive-multiple-sclerosis-remyelination-neuroprotection-and-targeting-astrocytes

Behandle physikalisch-medizinisch und bei vitaler Indikation zusätzlich mit Antibiotika, dann aber gezielt (möglichst kausal), hart und so frühzeitig wie möglich. Gegenanzeigen bitte beachten http://www.kabilahsystems.de/gegen.pdf

Treat physically, probiotic and in case of vital indication additionally with antibiotics, but then targeted (if possible causally), hard and as early as possible. Please note contraindications http://www.xerlebnishaft.de/gegen_eng.pdf

- ➔ **Therapievariante 2** http://www.kabilahsystems.de/therap_02_virus.pdf
- ➔ **Therapievariante 8** http://www.kabilahsystems.de/therap_08_protozoen_oder_hefen.pdf
- ➔ **Therapievariante 9** http://www.kabilahsystems.de/therap_09_bei_mikrofilariose.pdf

- ➔ **Therapie – Empfehlungen bei chronischen Multiinfektionskrankheiten**
  Treatment recommendations in chronic multi infectious diseases

Für alle chronischen Multisystem – Krankheiten durch Krankheitserreger gilt als Behandlungs – Muster der Ratgeber für Tuberkulose aus dem Robert Koch Institut (RKI).
https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Tuberkulose.html#doc2374486bodyText10

Bei allen Patienten mit chronischen Multisystem-Krankheiten die durch Krankheits-Erreger verursacht werden solten dreier-, vierer-, oder fünfer – Kombinationen von Antibiotika verabreicht werden und zwar über Zeiträume von (3), 6, 12, 18 Monate und auch weitaus länger. Ein Verabreichungs – Zeitraum der kürzer ist als 12 Monate ist in der Regel ineffektiv. Erfahrungsgemäß dauert die Kombinations-Langzeit-Antibiose bei Patienten mit chronischen Krankheiten durch Krankheits-Erreger so lange wie das Krankheitsbild schon Bestanden hatte. Vorsorglich sollte einschleichend medikamentiert werden („Herxheimer Reaktion" http://www.kabilahsystems.de/herxh.pdf http://www.xerlebnishaft.de/eosinophilie.pdf).

Folgen Sie den Bedürfnissen des Patienten. Eine häufige Strategieänderung bei der Auswahl von Antibiotika, auch Intervalltherapien sowie mehrfach angewendete sehr kurzzeitige Intervalltherapien bei akuten Krankheitsschüben sind in manchen Fällen und auf lange Sicht wirksam.

Medikamentöse Adjuvantien:
Probiotika http://www.kabilahsystems.de/probiotika.pdf
Gelbwurz, Pfeffer, Chilli http://www.kabilahsystems.de/pfefferchilligelbwurz.pdf
s.a. http://www.kabilahsystems.de/phytotherapie.pdf

For all chronic multisystem diseases caused by pathogens, the guide to tuberculosis from the Robert Koch Institute (RKI), Germany, applies in principle and analogously as a treatment pattern.
https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Tuberkulose.html#doc2374486bodyText10

Never administer a single antibiotic in patients with chronic multisystem diseases caused by pathogens. Always administer a combination of three or four or five antibiotics for a period of (3), 6, 12, 18 months or over a much longer period. Delivery times shorter than 12 months are meaningless. As a rule of thumb, the long-term antibiotic combination in patients with chronic diseases due to pathogens lasts as long as the disease had already existed. If necessary, medicate by sneaking in.

Follow the patient´s needs. A frequent strategy change in the selection of antibiotics, even interval therapies and also repeatedly applied very short-timed interval therapies in acute exacerbations are effective in the long view in some cases.

Medicinal adjuvants:
Probiotics http://www.kabilahsystems.de/probiotika.pdf
Turmeric, pepper, chilli http://www.kabilahsystems.de/pfefferchilligelbwurz.pdf
See also http://www.kabilahsystems.de/phytotherapie.pdf

Back to top http://www.erlebnishaft.de/multiplesklerose borreliose.pdf